Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
AngioScore logo — company profile

AngioScore

Founded 2003 United States Fremont, United States 56 employees Venture round Total: $87.00M Biotechnology, Health Care

General Information

Company Name AngioScore
Founded Year 2003
Location United States Fremont, United States
Employees 56
Industries Biotechnology, Health Care
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with AngioScore. To contact AngioScore, visit angioscore.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does AngioScore compare?

A PDF of AngioScore and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting AngioScore soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About AngioScore

AngioScore, founded in 2003, operates in the Biotechnology and Health Care industries, with its headquarters in the United States. The company's flagship product, the AngioSculpt Scoring Balloon Catheter, has revolutionized the treatment of peripheral arterial disease (PAD) and coronary artery disease (CAD). The innovative nitinol scoring element enables precise and predictable dilatation across a wide range of lesion types, providing versatility and effectiveness. In April 2011, AngioScore secured a significant $12.00M Venture Round investment from Saints Capital, further validating the potential of its groundbreaking technology. This investment solidifies the company's position in the market and signifies investor confidence in its innovative approach to addressing critical medical conditions. With its pioneering technology and the backing of prominent investors, AngioScore is well-positioned for continued growth and impact in the healthcare landscape.

Business keywords: Interventional Cardiology, Peripheral Arterial Disease, Coronary Artery Disease, Nitinol Technology, Scoring Balloon Catheter, Medical Device Manufacturing

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round $12.00M 1
Saints Capital
Saints Capital
20 Apr 2011
Series E $30.00M 6
Pelion Venture Partners California Technology Ventures QuestMark Partners
Pelion Venture Partners, California Technology Ventures +4
09 Oct 2007
Series D $30.00M 3
Pelion Venture Partners QuestMark Partners
Pelion Venture Partners, QuestMark Partners +1
11 Apr 2006
Series B $15.00M -
23 Aug 2004

AngioScore Alternatives & Competitors

View All Alternatives
AngioScore vs
SpectraWAVE, Inc.
SpectraWAVE, Inc. United States

Improving coronary artery disease outcomes with optical and computational insights.

Series B
56 employees
Biotechnology, Health Care
AngioScore vs
Cardiovascular Systems, Inc.
Cardiovascular Systems, Inc. United States

Cardiovascular Systems, Inc. (CSI) is committed to providing innovative solutions for the revascular...

Post-IPO Debt
343 employees
Biotechnology, Health Care
AngioScore vs
Reven Pharmaceuticals
Reven Pharmaceuticals United States

Diligently pursuing scientific innovation to exponentially improve health and well-being.

Series D
14 employees
Biotechnology, Health Care
View all alternatives

FAQ About AngioScore

The AngioSculpt Scoring Balloon Catheter significantly alters the landscape for treating both peripheral arterial disease (PAD) and coronary artery disease (CAD). The innovative nitinol scoring element scores the plaque circumferentially, providing a precise and predictable dilatation across a wide...
AngioScore was founded in 2003.
AngioScore is headquartered in Fremont, United States.
AngioScore operates in Biotechnology and Health Care. Its work centres on Interventional Cardiology, Peripheral Arterial Disease, Coronary Artery Disease and Nitinol Technology.
AngioScore has approximately 56 employees.
AngioScore has completed 4 funding rounds, raising a total of $87.00M. The latest funding stage is Venture round.
Top alternatives and competitors to AngioScore include SpectraWAVE, Inc., Cardiovascular Systems, Inc., Reven Pharmaceuticals, CryoTherapeutics SA, Lutonix, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
AngioScore and SpectraWAVE, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for AngioScore, https://bouncewatch.com/company/angioscore, updated 10 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes